Oxford BioMedica (OTCMKTS:OXBDF) Stock Jumps 15% – Still a Buy?

Oxford BioMedica (OTCMKTS:OXBDF)’s share price rose 15% during trading on Tuesday. The company traded as high as $7.65 and last traded at $7.65. 100 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 5,962 shares. The stock had previously closed at $6.65.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Oxford BioMedica to a “hold” rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Oxford BioMedica presently has an average rating of “Hold”.

Oxford BioMedica Price Performance

The company has a 50-day moving average price of $6.94 and a 200-day moving average price of $7.67.

About Oxford BioMedica

Oxford BioMedica plc is a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company works with biotechnology and pharmaceutical customers to develop, manufacture and test viral vectors and other biological materials used in advanced therapies.

Its capabilities include process and analytical development, clinical and commercial manufacturing, quality control, regulatory support and technology transfer. Oxford BioMedica has particular expertise in lentiviral vectors, which are used to deliver genetic material into cells, and also provides services involving adeno-associated virus and other viral-vector platforms.

Founded in 1995 and headquartered in Oxford, England, the company serves customers internationally across the pharmaceutical and biotechnology industries.